Could the properties of IL-27 make it an ideal adjuvant for anticancer immunotherapy?
We have recently been the first to demonstrate that interleukin (IL)-27 protects against the emergence and progression of autochthonous tumors. Accumulating evidence suggests that IL-27 might be uniquely well positioned to amplify beneficial TH1 anticancer immune responses while suppressing the unwanted accumulation of regulatory T cells.
|Authors||Swarbrick, A.; Junankar, S. R.; Batten, M.;|
|Responsible Garvan Author|
|URL link to publisher's version||http://www.ncbi.nlm.nih.gov/pubmed/24083081|
|OpenAccess link to author's accepted manuscript version||https://publications.gimr.garvan.org.au/open-access/11889|